Investment in R&D and Talent Development
First written in FY2016. 26 of 33 entries say "Restated". Latest entry: FY2026.
6 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The Group's research and development expenses for the fiscal year were ¥740 million.」
States that research and development activities continued and discloses research and development expenses of ¥740 million. This was an increase from ¥544 million in the previous fiscal year. - FY2026-H1RestatedAnnual report
「Total research and development expenses for the interim consolidated accounting period was ¥344 million. There were no significant changes in the status of the Group's research and development activities during the interim consolidated accounting period.」
States that there were no significant changes in research and development activities and discloses research and development expenses of ¥344 million for the interim consolidated accounting period. - FY2025Update full-year R&D expensesAnnual report
「The Group's R&D expenses for the consolidated fiscal year were ¥544 million.」
States that investment in research and development continued and discloses research and development expenses of ¥544 million for the fiscal year ending March 2025. This was a decrease from ¥614 million in the previous fiscal year. - FY2025-H1RestatedAnnual report
「Total R&D expenses for the interim consolidated cumulative period were ¥238 million. There were no material changes in the status of the Group's R&D activities during the interim consolidated cumulative period.」
States that investment in research and development continued and discloses research and development expenses of ¥238 million for the interim consolidated accounting period. It states that there were no significant changes in the status of the activities. - FY2024AdvancedAnnual report
「The Group's R&D expenses for the consolidated fiscal year were ¥614 million.」
States that investment in research and development continued and discloses research and development expenses of ¥614 million for the fiscal year. This was an increase from ¥515 million in the previous fiscal year. - FY2024-Q3RestatedAnnual report
「Total research and development expenses for the nine-month cumulative period was ¥447 million. There were no significant changes in the status of the Group's research and development activities during the nine-month cumulative period.」
States that there were no significant changes in research and development activities and discloses research and development expenses of ¥447 million for the nine-month cumulative period. - FY2024-Q2RestatedAnnual report
「Total research and development expenses for the six-month cumulative period was ¥296 million. There were no significant changes in the status of the Group's research and development activities during the six-month cumulative period.」
States that there were no significant changes in research and development activities and discloses research and development expenses of ¥296 million for the second quarter cumulative period. - FY2024-Q1RestatedAnnual report
「Total research and development expenses for the three-month cumulative period was ¥113 million. There were no significant changes in the status of the Group's research and development activities during the three-month cumulative period.」
States that there were no significant changes in research and development activities and discloses research and development expenses of ¥113 million for the three-month cumulative period. This was an increase from ¥107 million in the same period of the previous year. - FY2023-Q3RestatedAnnual report
「Total research and development expenses for the nine-month cumulative period was ¥397 million. There were no significant changes in the status of the Group's research and development activities during the nine-month cumulative period.」
States that there were no significant changes in research and development activities and discloses research and development expenses of ¥397 million for the nine-month cumulative period. - FY2023-Q2RestatedAnnual report
「To further enhance corporate value, the Company will actively invest in research and development and human resources development」
Reiterates the policy of continuing investment in research and development and human resources development as means of enhancing corporate value. Research and development expenses were ¥268 million for the six-month cumulative period. - FY2023-Q1RestatedAnnual report
「To further enhance corporate value, the Company will actively invest in research and development and human resources development and further strengthen its technological development capabilities, consulting sales capabilities, and manufacturing and sales capabilities, which are sources of the Company's corporate value.／Total research and development expenses for the three-month cumulative period was ¥107 million. There were no significant changes in the status of the Group's research and development activities during the three-month cumulative period.」
Reiterates the strengthening of the sources of corporate value through investment in research and development and human resources development, and states that research and development expenses were ¥107 million for the first quarter and that there were no significant changes in research and development activities. - FY2022-Q2RestatedAnnual report
「Total research and development expenses for the six-month cumulative period was ¥248 million. There were no significant changes in the status of the Group's research and development activities during the six-month cumulative period.」
States that there were no significant changes in research and development activities and discloses research and development expenses of ¥248 million for the six-month cumulative period. - FY2022-Q1RestatedAnnual report
「To further enhance corporate value, the Company will actively invest in research and development and human resources development and further strengthen its technological development capabilities, consulting sales capabilities, and manufacturing and sales capabilities, which are sources of the Company's corporate value.／Total research and development expenses for the three-month cumulative period was ¥53 million.」
Reiterates the strengthening of the sources of corporate value through investment in research and development and human resources development and discloses research and development expenses of ¥53 million for the first quarter. It states that there were no significant changes in research and development activities. - FY2021AdvancedAnnual report
「The Group's R&D expenses for the consolidated fiscal year were ¥313 million.」
States that investment in research and development continued and discloses research and development expenses of ¥313 million for the fiscal year. This was an increase from ¥305 million in the previous fiscal year. - FY2021-Q3RestatedAnnual report
「Total research and development expenses for the nine-month cumulative period was ¥210 million. There were no significant changes in the status of the Group's research and development activities during the nine-month cumulative period.」
States that there were no significant changes in research and development activities and discloses research and development expenses of ¥210 million for the nine-month cumulative period. - FY2021-Q2RestatedAnnual report
「Total research and development expenses for the six-month cumulative period was ¥140 million. There were no significant changes in the status of the Group's research and development activities during the six-month cumulative period.」
Reiterates the explanation that there were no significant changes in research and development activities and discloses research and development expenses of ¥140 million for the six-month cumulative period. - FY2021-Q1RestatedAnnual report
「Total research and development expenses for the three-month cumulative period was ¥71 million. There were no significant changes in the status of the Group's research and development activities during the three-month cumulative period.」
Reiterates the previous explanation that there were no significant changes in research and development activities and discloses research and development expenses of ¥71 million for the three-month cumulative period. - FY2020AdvancedAnnual report
「The Group's R&D expenses for the consolidated fiscal year were ¥305 million.」
States that investment in research and development continued and discloses research and development expenses of ¥305 million for the fiscal year. This was an increase from ¥279 million in the previous fiscal year. - FY2020-Q3RestatedAnnual report
「Total R&D expenses for the nine-month period of the current fiscal year were ¥176 million. There were no material changes in the status of the group’s R&D activities during the nine-month period of the current fiscal year.」
Discloses research and development expenses of ¥176 million for the nine-month cumulative period and states that there were no significant changes in research and development activities. - FY2020-Q2RestatedAnnual report
「To further enhance corporate value, the Company will actively invest in research and development and human resources development and further strengthen its technological development capabilities, consulting sales capabilities, and manufacturing and sales capabilities, which are sources of the Company's corporate value.／Total research and development expenses for the six-month cumulative period was ¥147 million. There were no significant changes in the status of the Group's research and development activities during the six-month cumulative period.」
Reiterates the strengthening of the sources of corporate value through investment in research and development and human resources development, and states that research and development expenses were ¥147 million for the six-month cumulative period and that there were no significant changes in research and development activities. - FY2020-Q1RestatedAnnual report
「To further enhance corporate value, the Company will actively invest in research and development and human resources development and further strengthen its technological development capabilities, consulting sales capabilities, and manufacturing and sales capabilities, which are sources of the Company's corporate value.／Total research and development expenses for the three-month cumulative period was ¥105 million.」
Reiterates the strengthening of the sources of corporate value through investment in research and development and human resources development and discloses research and development expenses of ¥105 million for the three-month cumulative period. It states that there were no significant changes in research and development activities. - FY2019RestatedAnnual report
「The Group has established a coordinated research and development structure across the Group and is actively engaged in developing concrete products, construction technologies, and construction management technologies through coordination and cooperation with research and development organizations outside the Group.／The Group's research and development expenses for the fiscal year were ¥279 million.」
States that research and development activities continued and discloses collaboration with research and development organizations inside and outside the Group and research and development expenses of ¥279 million for the fiscal year. - FY2019-Q3RestatedAnnual report
「To further enhance corporate value, the Company will actively invest in research and development and human resources development and further strengthen its technological development capabilities, consulting sales capabilities, and manufacturing and sales capabilities, which are sources of the Company's corporate value.／Total research and development expenses for the nine-month cumulative period was ¥203 million. There were no significant changes in the status of the Group's research and development activities during the nine-month cumulative period.」
Reiterates the strengthening of the sources of corporate value through investment in research and development and human resources development, and states that research and development expenses were ¥203 million for the nine-month cumulative period and that there were no significant changes in research and development activities. - FY2019-Q2RestatedAnnual report
「Total research and development expenses for the six-month cumulative period was ¥152 million. There were no significant changes in the status of the Group's research and development activities during the six-month cumulative period.」
Reiterates the previous explanation that there were no significant changes in research and development activities and discloses research and development expenses of ¥152 million for the six-month cumulative period. - FY2019-Q1RestatedAnnual report
「To further enhance corporate value, the Company will actively invest in research and development and human resources development and further strengthen its technological development capabilities, consulting sales capabilities, and manufacturing and sales capabilities, which are sources of the Company's corporate value.／Total research and development expenses for the three-month cumulative period was ¥24 million. There were no significant changes in the status of the Group's research and development activities during the three-month cumulative period.」
Reiterates the strengthening of the sources of corporate value through investment in research and development and human resources development, and states that research and development expenses were ¥24 million for the first quarter and that there were no significant changes in research and development activities. - FY2018AdvancedAnnual report
「The Group's research and development expenses for the fiscal year were ¥293 million.」
States that research and development activities continued and discloses research and development expenses of ¥293 million for the fiscal year. This was an increase from ¥240 million in the previous fiscal year. - FY2018-Q3RestatedAnnual report
「Total research and development expenses for the nine-month cumulative period was ¥245 million. There were no significant changes in the status of the Group's research and development activities during the nine-month cumulative period.」
Discloses research and development expenses of ¥245 million for the nine-month cumulative period and states that there were no significant changes in research and development activities. - FY2018-Q2RestatedAnnual report
「To further enhance our corporate value, we will actively invest in research and development and human resources development, while further strengthening the technological development, consultative sales, and manufacturing and sales capabilities that are sources of our corporate value.」
Reiterates the strengthening of the sources of corporate value through investment in research and development and human resources development. It states that research and development expenses were ¥117 million for the six-month cumulative period and that there were no significant changes in the status of the activities. - FY2018-Q1RestatedAnnual report
「Total research and development expenses for the three-month cumulative period was ¥40 million. There were no significant changes in the status of the Group's research and development activities during the three-month cumulative period.」
States that there were no significant changes in research and development activities and discloses research and development expenses of ¥40 million for the three-month cumulative period. - FY2017-Q3RestatedAnnual report
「Total research and development expenses for the nine-month cumulative period was ¥178 million. There were no significant changes in the status of the Group's research and development activities during the nine-month cumulative period.」
Discloses research and development expenses of ¥178 million for the nine-month cumulative period and states that there were no significant changes in research and development activities. - FY2017-Q2RestatedAnnual report
「Total research and development expenses for the six-month cumulative period was ¥143 million. There were no significant changes in the status of the Group's research and development activities during the six-month cumulative period.」
States that there were no significant changes in research and development activities and discloses research and development expenses of ¥143 million for the six-month cumulative period. - FY2017-Q1RestatedAnnual report
「Total research and development expenses for the three-month period of the current consolidated fiscal year were ¥86 million. There were no material changes in the status of the Group's research and development activities during the three-month period of the current consolidated fiscal year.」
States that there have been no significant changes in research and development activities and discloses research and development expenses of ¥86 million for the quarter. - FY2016First statedAnnual report
「To further enhance corporate value, we will actively invest in research and development and human resources development」
Identifies investment in research and development and human resources development as means of enhancing corporate value.